VivoSeq
Other

Erythroplakia

1

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Erythroplakia is an early-stage landscape with 1 program across 1 company. The most active players are Boehringer Ingelheim.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Metformin Hydrochloride

Boehringer Ingelheim

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

1

clinical trials

Active, not recruiting1 · 100%

Clinical Trials

Trial Activity

M4OC-Prevent: Metformin for Oral Cancer Prevention
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT02581137·26 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)